Navigation Links
New Boehringer Ingelheim Oncology Data to be Presented at ESMO 2012 Congress
Date:9/20/2012

RIDGEFIELD, Conn., Sept. 20, 2012 /PRNewswire/ -- Boehringer Ingelheim today announced that data from 13 abstracts assessing the efficacy and safety of two of its investigational oncology compounds – afatinib and nintedanib – were selected for presentation at the ESMO 2012 Congress (European Society for Medical Oncology) in Vienna, Austria, September 28 – October 2, 2012.  These data represent Boehringer Ingelheim's commitment to further develop its oncology pipeline with the goal of bringing new treatment options to the oncology community.

Data will include results from Phase II and III studies of afatinib in various lung cancer treatment settings and patient groups as well as data on health-related quality of life and symptom control.  Data from Phase I studies of afatinib in advanced solid tumors will also be presented.  The nintedanib results are from Phase I studies in hepatocellular carcinoma and in combination with afatinib in advanced solid tumors.

"Boehringer Ingelheim is looking forward to sharing new results for our investigational oncology compounds with the global oncology community at ESMO," said Berthold Greifenberg, M.D., vice president, Clinical Development and Medical Affairs, Oncology, Boehringer Ingelheim Pharmaceuticals, Inc. "This is an exciting time for Boehringer Ingelheim as we continue to explore the potential of our growing oncology pipeline."

 

Data for Boehringer Ingelheim Investigational Oncology Compounds at ESMO 2012TitleLead Study AuthorAbstract DetailsAfatinib*LUX-Lung 3: Activity of afatinib in uncommon epidermal growth factor receptor (EGFR) mutations in LUX-Lung 3, a phase III trial of afatinib or cisplatin/pemetrexed in EGFR mutation-positive lung cancer

James Chih-Hsin Yang,

MD, PhD

ESMO Abstract # 1252P
Date: Saturday, September 29
Time: 13:00 – 14:00 PM CESTPhase II trial of afatinib as a third-line treatme
'/>"/>

SOURCE Boehringer Ingelheim
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. MacroGenics Receives Milestone Payment as Part of Its Global DART™ Alliance with Boehringer Ingelheim
2. Symphogen Grants Exclusive Worldwide License of Phase II Oncology Drug Candidate Sym004 to Merck KGaA
3. 500 Oncology Providers Sign Up for Navigating Cancers Patient Engagement Portal
4. Champions Oncology Reports Financial Results for the Year Ended April 30, 2012
5. Champions Oncology Inc. Receives Approval from U.S. Regulatory Authorities
6. Sofie Biosciences Is Awarded a US Patent on a Family of Novel PET Probes for Use in Oncology and Immunology
7. Former Sanofi-aventis and US Oncology Executive Joins New Century Health as Chief Executive Officer
8. OvaGene Oncology Collaborates With Moffitt Cancer Center to Develop and Commercialize microRNAs Associated With Chemotherapeutic Drug Response
9. US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium
10. Data From Phase II Trial of Prolor Biotechs Long-acting Human Growth Hormone Presented at Endo 2012
11. Startling results in synthetic chemistry presented in Nature Chemistry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... 27, 2015 Junto Health, a company that ... and develop new technology solutions, today announced the launch ... a leader in health care policy consulting. Working together ... a collaborative innovation process while, at the same time, ... public policy, health care finance and the delivery of ...
(Date:7/24/2015)... , July 24, 2015 Ryan & Maniskas, ... in United States District Court for the Northern District of ... or entities that purchased the common stock of Avalanche Biotechnologies, ... July 31, 2014 and June 15, 2015, inclusive (the "Class ... 8, 2015, move the Court for appointment as a lead ...
(Date:7/24/2015)... Agritech Limited (NASDAQ GS: SEED) ("Origin", or the "Company"), a ... , today announced that the Company will report results for ... before the market opens on Wednesday, August 5th, 2015. ... 2015, at 9:00 a.m. ET / 9:00 p.m. ... in the call, please dial the following numbers approximately 5 ...
(Date:7/23/2015)... ... ... The health and wellness of brain tumor caregivers, often a spouse, parent, sibling ... American Brain Tumor Association presents interactive sessions that address shifting the mindset of caregivers ... Chicago. , “We have understood for a long-time now that caregivers and families ...
Breaking Biology Technology:Junto Health Announces a Unique Partnership with Sachs Policy Group 2Junto Health Announces a Unique Partnership with Sachs Policy Group 3Junto Health Announces a Unique Partnership with Sachs Policy Group 4Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Avalanche Biotechnologies, Inc. 2Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Avalanche Biotechnologies, Inc. 3Origin Agritech Limited to Announce Third Quarter Fiscal 2015 Unaudited Financial Results on August 5th, 2015 2Origin Agritech Limited to Announce Third Quarter Fiscal 2015 Unaudited Financial Results on August 5th, 2015 3Reframing the Caregiver and Patient Mindset: Coping with the ‘New Normal’ 2Reframing the Caregiver and Patient Mindset: Coping with the ‘New Normal’ 3
... -- LEUVEN, Belgium, September 30, 2010 ... ... ... are keyed by longUrl, so we need to grab the first one. for (var r in data.results) ...
... While refining their novel method for making nanoscale ... and Technology (NIST) discovered an unexpected bonusa new ... to that from light-emitting diodes (LEDs). These "nano-LEDs" ... to work serving miniature devices such as nanogenerators ...
... Sept. 29 /PRNewswire-FirstCall/ - Generex Biotechnology Corporation (Nasdaq: ... development, and commercialization of drug delivery systems and technologies, ... Mark Fletcher as Interim President and Chief Executive Officer ... an independent director, to serve as Chairman of the ...
Cached Biology Technology:ThromboGenics Signs Deal With MSD for Long-Term Commercial Supply of Microplasmin 2ThromboGenics Signs Deal With MSD for Long-Term Commercial Supply of Microplasmin 3ThromboGenics Signs Deal With MSD for Long-Term Commercial Supply of Microplasmin 4ThromboGenics Signs Deal With MSD for Long-Term Commercial Supply of Microplasmin 5ThromboGenics Signs Deal With MSD for Long-Term Commercial Supply of Microplasmin 6ThromboGenics Signs Deal With MSD for Long-Term Commercial Supply of Microplasmin 7ThromboGenics Signs Deal With MSD for Long-Term Commercial Supply of Microplasmin 8Growing nanowires horizontally yields new benefit: 'nano-LEDs' 2Generex Biotechnology Appoints Mark Fletcher as Interim President and CEO, and John P. Barratt as Chairman of the Board 2Generex Biotechnology Appoints Mark Fletcher as Interim President and CEO, and John P. Barratt as Chairman of the Board 3
(Date:7/2/2015)... DUBLIN , June 25, 2015 ... the addition of the "Next Generation Biometrics Market ... to 2020" report to their offering. ... $24.4 Billion by 2020, at a CAGR of 17.9% ... is the leading application for the market. Safran ...
(Date:6/26/2015)... SPRINGVILLE, Utah , June 26, 2015 ATL ... assemblies and devices with specialties in single use solutions, headquartered ... acquisition of MedConx, Inc. (a California ... , and San Jose, Costa Rica ). ... Costa Rica with ATL Technology,s existing ...
(Date:6/24/2015)... , June 24, 2015 This report provides ... the next six years. It contains an analysis of ... along with their impact from the short, medium, and ... discusses the industry, market, and technology trends that currently, ... need of concerned authorities to efficiently manage the increasing ...
Breaking Biology News(10 mins):Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2
... In January 2012, the United States Department of Agriculture ... lunches more nutritious, which included requiring schools to increase ... fruit or vegetable with their purchased lunch. However, children ... a new study scheduled for publication in The ...
... the western Pacific Ocean may be losing their last ... to a paper published today in the scientific journal ... Researchers from the State University of Papua ... and World Wildlife Fund Indonesia released a report today ...
... The COMBACTE (Combatting Bacterial Resistance in Europe) project, resulting ... IMI, is one of the projects that is part ... It is the result of the initial association between ... run respectively by Marc Bonten of the University of ...
Cached Biology News:Libertarian paternalism and school lunches: Guiding healthier behavior while preserving choices 2New study shows continued decline in the last remaining stronghold for leatherback sea turtles 2COMBACTE: A new step in the fight against resistance to antibiotics 2COMBACTE: A new step in the fight against resistance to antibiotics 3
... stands both present the shaker ... and help protect user safety. ... steel, these heavy-duty accessories are ... and minimize the vibration produced ...
... (RNA polymers) are prepared ... of the enzyme, polynucleotide ... and the appropriate, ribonucleoside ... the exception of catalog ...
...
Anti-Tissue Trans-glutaminase (IgA) EIA Sample Size: 10 l...
Biology Products: